These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7907009)

  • 1. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice.
    Jabs DA; Kuppers RC; Saboori AM; Burek CL; Enger C; Lee B; Prendergast RA
    Cell Immunol; 1994 Mar; 154(1):66-76. PubMed ID: 7907009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Burek CL; Hu Q; Kuppers RC; Lee B; Prendergast RA
    Cell Immunol; 1992 May; 141(2):496-507. PubMed ID: 1576659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of T cells in the pathogenesis of autoimmune lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Lee B; Prendergast RA
    Curr Eye Res; 1997 Sep; 16(9):909-16. PubMed ID: 9288452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxic effect of anti-CD4 therapy on lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Burns WH; Prendergast RA
    Invest Ophthalmol Vis Sci; 1996 Jan; 37(1):246-50. PubMed ID: 8550330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune ocular disease in MRL/Mp-lpr/lpr mice is suppressed by anti-CD4 antibody.
    Jabs DA; Prendergast RA
    Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2718-22. PubMed ID: 1680111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis.
    Harper JM; Cook A
    Autoimmunity; 2001; 33(4):245-51. PubMed ID: 11683399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice.
    Jabs DA; Lee B; Burek CL; Saboori AM; Prendergast RA
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):377-83. PubMed ID: 8603842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
    Seaman WE; Wofsy D; Greenspan JS; Ledbetter JA
    J Immunol; 1983 Apr; 130(4):1713-8. PubMed ID: 6187819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
    Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
    J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term anti-CD4 or anti-CD8 treatment on the development of lpr CD4- CD8- double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice.
    Merino R; Fossati L; Iwamoto M; Takahashi S; Lemoine R; Ibnou-Zekri N; Pugliatti L; Merino J; Izui S
    J Autoimmun; 1995 Feb; 8(1):33-45. PubMed ID: 7734035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
    Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
    Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term anti-CD4 treatment of MRL/lpr mice ameliorates immunopathology and lymphoproliferation but fails to suppress rheumatoid factor production.
    O'Sullivan FX; Ray CJ; Takeda Y; Sharp GC; Walker SE
    Clin Immunol Immunopathol; 1991 Dec; 61(3):421-35. PubMed ID: 1934630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody.
    Henrickson M; Giannini EH; Hirsch R
    Arthritis Rheum; 1994 Apr; 37(4):587-94. PubMed ID: 8147938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for major alterations in the thymocyte subpopulations in murine models of autoimmune diseases.
    Kakkanaiah VN; Pyle RH; Nagarkatti M; Nagarkatti PS
    J Autoimmun; 1990 Jun; 3(3):271-88. PubMed ID: 1975741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.
    Zhang MC; Misu N; Furukawa H; Watanabe Y; Terada M; Komori H; Miyazaki T; Nose M; Ono M
    Ann Rheum Dis; 2006 Apr; 65(4):495-500. PubMed ID: 16150787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
    Fujii T; Okada M; Fujita Y; Sato T; Tanaka M; Usui T; Umehara H; Mimori T
    J Autoimmun; 2009 Sep; 33(2):125-34. PubMed ID: 19596182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
    Merino R; Iwamoto M; Fossati L; Izui S
    J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice.
    Furukawa F; Kanauchi H; Wakita H; Tokura Y; Tachibana T; Horiguchi Y; Imamura S; Ozaki S; Takigawa M
    J Invest Dermatol; 1996 Jul; 107(1):95-100. PubMed ID: 8752846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of autoimmune disease and lymphocyte accumulation in MRL/lpr mice by treatment with anti-V beta 8 antibodies.
    de Alborán IM; Gonzalo JA; Kroemer G; Leonardo E; Marcos MA; Martínez C
    Eur J Immunol; 1992 Aug; 22(8):2153-8. PubMed ID: 1386316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.